pioglitazone has been researched along with Pregnancy in 40 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although the number of follicles was higher in the pioglitazone group, our study showed no differences in ovary stimulation and pregnancy rate." | 9.41 | Combination of pioglitazone and clomiphene citrate versus clomiphene citrate alone for infertile women with the polycystic ovarian syndrome. ( Amirian, M; Jafarian, F; Mirteimouri, M; Nikdoust, S; Niroumand, S; Payrovnaziri, A; Salehi, M; Shariat Moghani, S, 2021) |
| "To investigate the effects of pioglitazone on ovarian stimulation, in vitro fertilization (IVF) outcome, and intraovarian stromal blood flow in patients with polycystic ovary syndrome (PCOS)." | 9.14 | Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome. ( Chae, HD; Jeon, GH; Kang, BM; Kim, CH; Kim, SH; Kim, SR, 2010) |
| "To investigate the efficacy of pioglitazone on fecundity in infertile patients with polycystic ovary syndrome (PCOS) who are resistant to conventional ovulation induction such as clomiphene, dexamethasone, or metformin." | 9.13 | Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome. ( Goto, T; Ohyama, N; Ota, H; Yoshioka, T, 2008) |
| " The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment." | 9.11 | Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. ( Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A, 2005) |
| " Insulin-sensitising agents such as metformin may be effective in treating PCOS-related anovulation." | 8.95 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E, 2017) |
| "Pioglitazone treatment significantly improved LPS-induced neurobehavioral and physiological disturbances including the loss of body weight, hypothermia, righting reflex, wire-hanging maneuver, negative geotaxis, and hind-limb suspension in neonatal rats." | 5.62 | Pioglitazone Ameliorates Lipopolysaccharide-Induced Behavioral Impairment, Brain Inflammation, White Matter Injury and Mitochondrial Dysfunction in Neonatal Rats. ( Fan, LW; Kaizaki, A; Lee, JW; Ojeda, NB; Tien, LT; Tucci, MA; Wang, KC; Wei, HC; Yeh, JH, 2021) |
| "A total of 27 RCTs with 12 interventions were included, and all therapies tended to increase clinical pregnancy, especially pioglitazone (PIO) (log OR 3." | 5.41 | The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis. ( Li, J; Liu, Y; Ma, J; Peng, G; Tong, N; Wang, Y; Yan, Z, 2023) |
| "Although the number of follicles was higher in the pioglitazone group, our study showed no differences in ovary stimulation and pregnancy rate." | 5.41 | Combination of pioglitazone and clomiphene citrate versus clomiphene citrate alone for infertile women with the polycystic ovarian syndrome. ( Amirian, M; Jafarian, F; Mirteimouri, M; Nikdoust, S; Niroumand, S; Payrovnaziri, A; Salehi, M; Shariat Moghani, S, 2021) |
| "To investigate the effects of pioglitazone on ovarian stimulation, in vitro fertilization (IVF) outcome, and intraovarian stromal blood flow in patients with polycystic ovary syndrome (PCOS)." | 5.14 | Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome. ( Chae, HD; Jeon, GH; Kang, BM; Kim, CH; Kim, SH; Kim, SR, 2010) |
| "To investigate the efficacy of pioglitazone on fecundity in infertile patients with polycystic ovary syndrome (PCOS) who are resistant to conventional ovulation induction such as clomiphene, dexamethasone, or metformin." | 5.13 | Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome. ( Goto, T; Ohyama, N; Ota, H; Yoshioka, T, 2008) |
| "The Pioglitazone In Prevention Of Diabetes (PIPOD) study was conducted to evaluate beta-cell function, insulin resistance, and the incidence of diabetes during treatment with pioglitazone in Hispanic women with prior gestational diabetes who had completed participation in the Troglitazone In Prevention Of Diabetes (TRIPOD) study." | 5.12 | Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. ( Buchanan, TA; Goico, J; Kawakubo, M; Kjos, SL; Marroquin, A; Ochoa, C; Peters, RK; Xiang, AH, 2006) |
| " The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment." | 5.11 | Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. ( Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A, 2005) |
| "To investigate whether the long-term administration of metformin or pioglitazone to women with polycystic ovary syndrome (PCOS) could induce changes in their hypothalamic dopaminergic (DA) tone and to analyze whether these changes correlated with modifications in insulin resistance, we originally studied 57 obese hyperinsulinemic, non-diabetic, insulin resistant women with PCOS, but only 34 completed the study." | 5.11 | Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. ( Arteaga-Troncoso, G; Cardoza, L; Coutiño, B; Hidalgo, R; Ortega-González, C; Parra, A, 2005) |
| " Insulin-sensitising agents such as metformin may be effective in treating PCOS-related anovulation." | 4.95 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E, 2017) |
| " Considering the role of renin-angiotensin system (RAS) in maternal programming during PE, we investigated the hypothesis that gestational modulation of offensive (Angiotensin II, Ang II) and defensive (Ang 1-7) components of RAS alleviates cardiovascular hyperresponsiveness of weaning PE mothers to postpartum endotoxemia." | 4.12 | Dysregulated ACE/Ang II/Ang1-7 signaling provokes cardiovascular and inflammatory sequelae of endotoxemia in weaning preeclamptic rats. ( Abuiessa, SA; El-Gowelli, HM; El-Gowilly, SM; El-Mas, MM; Helmy, MM, 2022) |
| " Here, we used a model of HA pregnancy in mice to determine whether hypoxia-induced fetal growth restriction reduces placental PPAR-γ protein expression and placental vascularization and, if so, to evaluate the effectiveness of the selective PPAR-γ agonist pioglitazone (PIO) for preventing hypoxia-induced IUGR." | 3.91 | Pharmacological activation of peroxisome proliferator-activated receptor γ (PPAR-γ) protects against hypoxia-associated fetal growth restriction. ( Dodson, RB; Doyle, AS; Julian, CG; Lane, SL; Lorca, RA; Matarrazo, CJ; Moore, LG; Park, H; Rathi, H; Wolfson, GH, 2019) |
| "Catechol-O-methyltransferase (COMT) metabolizes 2-hydroxyestradiol into 2-methoxyestradiol (2-ME); COMT deficiency has shown to be associated with hypertension in men and preeclampsia, the disease associated with hypersensitivity of pressor response against angiotensin II (Ang II)." | 3.85 | Catechol-O-Methyltransferase Deficiency Leads to Hypersensitivity of the Pressor Response Against Angiotensin II. ( Kanasaki, K; Kanasaki, M; Koya, D; Takeda, S; Ueki, N, 2017) |
| "Women with a history of gestational diabetes are at high risk for developing type 2 diabetes mellitus." | 2.55 | Preventing progression from gestational diabetes mellitus to diabetes: A thought-filled review. ( Grajower, MM; Kasher-Meron, M, 2017) |
| "Patients diagnosed with fetal alcohol spectrum disorder (FASD) show persistent cognitive disabilities, including memory deficits." | 1.91 | The role of PPAR-γ in memory deficits induced by prenatal and lactation alcohol exposure in mice. ( de la Torre, R; Gallego-Landin, I; Garcia-Baos, A; Pastor, A; Sanz, F; Valverde, O, 2023) |
| "Pioglitazone treatment significantly improved LPS-induced neurobehavioral and physiological disturbances including the loss of body weight, hypothermia, righting reflex, wire-hanging maneuver, negative geotaxis, and hind-limb suspension in neonatal rats." | 1.62 | Pioglitazone Ameliorates Lipopolysaccharide-Induced Behavioral Impairment, Brain Inflammation, White Matter Injury and Mitochondrial Dysfunction in Neonatal Rats. ( Fan, LW; Kaizaki, A; Lee, JW; Ojeda, NB; Tien, LT; Tucci, MA; Wang, KC; Wei, HC; Yeh, JH, 2021) |
| "Treatment with pioglitazone significantly attenuated the prenatal VPA-induced social impairment, repetitive behavior, hyperactivity, anxiety and low exploratory activity." | 1.51 | Beneficial effects of pioglitazone, a selective peroxisome proliferator-activated receptor-γ agonist in prenatal valproic acid-induced behavioral and biochemical autistic like features in Wistar rats. ( Mirza, R; Sharma, B, 2019) |
| "Pioglitazone is a peroxisome proliferator-activated receptor (PPAR)-γ agonist that exhibits anti-inflammatory activity and is neuroprotective." | 1.42 | Pioglitazone blocks ethanol induction of microglial activation and immune responses in the hippocampus, cerebellum, and cerebral cortex in a mouse model of fetal alcohol spectrum disorders. ( Douglas, JC; Drew, PD; Johnson, JW; Kane, CJ; Phelan, KD, 2015) |
| "Pioglitazone treatment increased energy expenditure and improved insulin resistance, hypotriglyceridaemia and liver steatosis in these mice." | 1.39 | Thiazolidinediones partially reverse the metabolic disturbances observed in Bscl2/seipin-deficient mice. ( Capeau, J; Cariou, B; Costet, P; Dollet, L; Fève, B; Lathrop, M; Le May, C; Magré, J; Matsuda, F; Mounier, C; Nemani, M; Pillot, B; Prieur, X; Takahashi, M; Takigawa-Imamura, H; Zelenika, D, 2013) |
| "Rodent models of FASD have previously demonstrated that both Purkinje cells and granule cells, which are the two major types of neurons in the cerebellum, are highly susceptible to the toxic effects of ethanol." | 1.37 | Protection of neurons and microglia against ethanol in a mouse model of fetal alcohol spectrum disorders by peroxisome proliferator-activated receptor-γ agonists. ( Douglas, JC; Drew, PD; Han, L; Kane, CJ; Phelan, KD; Smith, RR; Xie, J, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (30.00) | 29.6817 |
| 2010's | 16 (40.00) | 24.3611 |
| 2020's | 12 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kurzyńska, A | 2 |
| Kunicka, Z | 2 |
| Mierzejewski, K | 2 |
| Golubska, M | 2 |
| Bogacka, I | 2 |
| Stryiński, R | 1 |
| Mateos, J | 1 |
| Carrera, M | 1 |
| Abuiessa, SA | 1 |
| Helmy, MM | 1 |
| El-Gowelli, HM | 1 |
| El-Gowilly, SM | 1 |
| El-Mas, MM | 1 |
| Mirzaie, S | 2 |
| Yousefi, AR | 2 |
| Masoumi, R | 2 |
| Rostami, B | 2 |
| Amanlou, H | 2 |
| Chen, Z | 1 |
| E, Y | 1 |
| Xiong, J | 1 |
| Li, W | 1 |
| Chen, X | 1 |
| Li, N | 1 |
| Long, J | 1 |
| Tong, C | 1 |
| He, J | 1 |
| Li, F | 1 |
| Zhang, C | 1 |
| Wang, Y | 2 |
| Gao, R | 1 |
| Peng, G | 1 |
| Yan, Z | 1 |
| Liu, Y | 1 |
| Li, J | 1 |
| Ma, J | 1 |
| Tong, N | 1 |
| Garcia-Baos, A | 1 |
| Pastor, A | 1 |
| Gallego-Landin, I | 1 |
| de la Torre, R | 1 |
| Sanz, F | 1 |
| Valverde, O | 1 |
| Han, Y | 2 |
| Wang, J | 2 |
| Zhao, Q | 2 |
| Xie, X | 1 |
| Song, R | 1 |
| Xiao, Y | 1 |
| Kang, X | 1 |
| Zhang, L | 1 |
| Zhang, Y | 1 |
| Peng, C | 1 |
| You, Z | 2 |
| Liu, WC | 2 |
| Wu, CW | 2 |
| Fu, MH | 2 |
| Tain, YL | 2 |
| Liang, CK | 2 |
| Hung, CY | 2 |
| Chen, IC | 1 |
| Lee, YC | 1 |
| Wu, CY | 1 |
| Wu, KLH | 2 |
| Sağır, D | 1 |
| Yeh, JH | 1 |
| Wang, KC | 1 |
| Kaizaki, A | 1 |
| Lee, JW | 1 |
| Wei, HC | 1 |
| Tucci, MA | 1 |
| Ojeda, NB | 1 |
| Fan, LW | 1 |
| Tien, LT | 1 |
| Amirian, M | 1 |
| Shariat Moghani, S | 1 |
| Jafarian, F | 1 |
| Mirteimouri, M | 1 |
| Nikdoust, S | 1 |
| Niroumand, S | 1 |
| Salehi, M | 1 |
| Payrovnaziri, A | 1 |
| Ueki, N | 1 |
| Kanasaki, K | 1 |
| Kanasaki, M | 1 |
| Takeda, S | 1 |
| Koya, D | 1 |
| Kasher-Meron, M | 1 |
| Grajower, MM | 1 |
| Lian, QX | 1 |
| Deng, HZ | 1 |
| Chen, KY | 1 |
| Deng, H | 1 |
| Morley, LC | 1 |
| Tang, T | 1 |
| Yasmin, E | 1 |
| Norman, RJ | 1 |
| Balen, AH | 1 |
| Jamali Emam Gheise, N | 1 |
| Riasi, A | 1 |
| Celi, P | 1 |
| Shahneh, AZ | 1 |
| El Dairi, R | 1 |
| Huuskonen, P | 1 |
| Pasanen, M | 1 |
| Rysä, J | 1 |
| Wang, Q | 1 |
| Tang, M | 1 |
| Huang, S | 1 |
| Peng, K | 1 |
| Zhang, J | 1 |
| Liu, G | 1 |
| Fang, Q | 1 |
| Hirase, H | 1 |
| Lee, WC | 1 |
| Chan, JYH | 1 |
| Chen, LW | 1 |
| Ho, YH | 1 |
| Kung, YC | 1 |
| Leu, S | 1 |
| Lane, SL | 1 |
| Dodson, RB | 1 |
| Doyle, AS | 1 |
| Park, H | 1 |
| Rathi, H | 1 |
| Matarrazo, CJ | 1 |
| Moore, LG | 1 |
| Lorca, RA | 1 |
| Wolfson, GH | 1 |
| Julian, CG | 1 |
| Mirza, R | 1 |
| Sharma, B | 1 |
| Prieur, X | 1 |
| Dollet, L | 1 |
| Takahashi, M | 1 |
| Nemani, M | 1 |
| Pillot, B | 1 |
| Le May, C | 1 |
| Mounier, C | 1 |
| Takigawa-Imamura, H | 1 |
| Zelenika, D | 1 |
| Matsuda, F | 1 |
| Fève, B | 1 |
| Capeau, J | 1 |
| Lathrop, M | 1 |
| Costet, P | 1 |
| Cariou, B | 1 |
| Magré, J | 1 |
| Drew, PD | 2 |
| Johnson, JW | 1 |
| Douglas, JC | 2 |
| Phelan, KD | 2 |
| Kane, CJ | 2 |
| Kim, CH | 1 |
| Jeon, GH | 1 |
| Kim, SR | 1 |
| Kim, SH | 1 |
| Chae, HD | 1 |
| Kang, BM | 1 |
| Pancani, T | 1 |
| Phelps, JT | 1 |
| Searcy, JL | 1 |
| Kilgore, MW | 1 |
| Chen, KC | 1 |
| Porter, NM | 1 |
| Thibault, O | 1 |
| Han, L | 1 |
| Smith, RR | 1 |
| Xie, J | 1 |
| Mayama, R | 1 |
| Izawa, T | 1 |
| Sakai, K | 1 |
| Suciu, N | 1 |
| Iwashita, M | 1 |
| Kalanderian, A | 1 |
| Abate, N | 1 |
| Patrikeev, I | 1 |
| Wei, J | 1 |
| Vincent, KL | 1 |
| Motamedi, M | 1 |
| Saade, GR | 1 |
| Bytautiene, E | 1 |
| Papoushek, C | 1 |
| Füessl, HS | 1 |
| Ortega-González, C | 2 |
| Luna, S | 1 |
| Hernández, L | 1 |
| Crespo, G | 1 |
| Aguayo, P | 1 |
| Arteaga-Troncoso, G | 2 |
| Parra, A | 2 |
| Cardoza, L | 1 |
| Coutiño, B | 1 |
| Hidalgo, R | 1 |
| Xiang, AH | 2 |
| Peters, RK | 2 |
| Kjos, SL | 2 |
| Marroquin, A | 2 |
| Goico, J | 2 |
| Ochoa, C | 2 |
| Kawakubo, M | 2 |
| Buchanan, TA | 2 |
| Xing, B | 1 |
| Liu, M | 1 |
| Bing, G | 1 |
| Hodis, HN | 1 |
| Liu, CR | 1 |
| Liu, CH | 1 |
| Goldenberg, N | 1 |
| Glueck, C | 1 |
| Ota, H | 1 |
| Goto, T | 1 |
| Yoshioka, T | 1 |
| Ohyama, N | 1 |
| Yoon, JC | 1 |
| Chickering, TW | 1 |
| Rosen, ED | 1 |
| Dussault, B | 1 |
| Qin, Y | 1 |
| Soukas, A | 1 |
| Friedman, JM | 1 |
| Holmes, WE | 1 |
| Spiegelman, BM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS:A Double Blind Randomized Placebo Controlled Trial[NCT05653895] | 250 participants (Anticipated) | Interventional | 2022-12-07 | Recruiting | |||
| The Effects of Acetyl L--Carnitine and Myo/Chiro-Inositol on Improving Ovulation, Pregnancy Rate, Ovarian Function and Perceived Stress Response in Patients With PCOS[NCT05767515] | 120 participants (Anticipated) | Interventional | 2023-04-15 | Not yet recruiting | |||
| Effects of Metformin and Combination of Metformin and Pioglitazone on Plasma Interleukin-6 and Interleukin-8 Levels in Polycystic Ovarian Syndrome[NCT03117517] | Early Phase 1 | 106 participants (Actual) | Interventional | 2017-03-20 | Completed | ||
| Effect of Metformin and Combination of Olive Oil Plus Nutritional Supplements on Inflammatory Markers IL-6 and IL-8 in PCOS.[NCT05952349] | Phase 2 | 88 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| The Experience of Living With Polycystic Ovary Syndrome in the Military[NCT03876665] | 24 participants (Actual) | Observational | 2019-08-15 | Completed | |||
| A Multicenter Randomized Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth for Infertility in Women With Polycystic Ovary Syndrome[NCT03625531] | Phase 3 | 1,100 participants (Anticipated) | Interventional | 2018-08-13 | Recruiting | ||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| A Multicenter, Prospective, Randomized Study to Assess the Effect of Metformin Supplementation on IVF Outcome and Intrafollicular Environment in Patients With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization/Embryo Transfer[NCT03086005] | Phase 3 | 24 participants (Actual) | Interventional | 2011-10-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
IL-6 and IL-8 levels by ELISA method using commercially available kits. (NCT03117517)
Timeframe: Baseline and after 3 Months
| Intervention | pg/ml (Geometric Mean) | |||
|---|---|---|---|---|
| IL-6 levels at baseline | IL-6 levels after 3 months of treatment | IL-8 Llevels at baseline | IL-8 Llevels after treatment | |
| Metformin | 14.60 | 12.65 | 61.92 | 32.70 |
| Metformin, Pioglitazone | 14.12 | 11.12 | 41.86 | 22.00 |
Serum level of LH was measure at baseline and after 3 months of treatment (NCT03117517)
Timeframe: Baseine and after 3 Months
| Intervention | mIU/ml (Geometric Mean) | |
|---|---|---|
| LH level at baseline | LH level after treatment | |
| Metformin | 5.79 | 4.92 |
| Metformin, Pioglitazone | 6.625 | 5.16 |
Insulin resistance was measure by calculating HOMA-IR from the data of insulin and sugar levels. (NCT03117517)
Timeframe: Baseline and after 3 months
| Intervention | unitless (Mean) | |
|---|---|---|
| HOMA-IR at baseline | HOMA-IR after treatment | |
| Metformin | 7.19 | 3.97 |
| Metformin, Pioglitazone | 6.22 | 3.84 |
5 reviews available for pioglitazone and Pregnancy
| Article | Year |
|---|---|
The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis.
Topics: Abortion, Spontaneous; Clomiphene; Female; Humans; Infertility, Female; Live Birth; Metformin; Netwo | 2023 |
Preventing progression from gestational diabetes mellitus to diabetes: A thought-filled review.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Disease Progression; Female; Humans; Hypogl | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
The "glitazones": rosiglitazone and pioglitazone.
Topics: Contraindications; Diabetes Mellitus, Type 2; Drug Interactions; Female; Heart Failure; Humans; Hypo | 2003 |
Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation.
Topics: Adult; Clomiphene; Diabetes, Gestational; Drug Therapy, Combination; Female; Fertility Agents, Femal | 2008 |
9 trials available for pioglitazone and Pregnancy
| Article | Year |
|---|---|
The effect of dietary pioglitazone supplementation on milk yield, insulin sensitivity and GH-IGF-I axis in Holstein dairy cows during the transition period.
Topics: Animals; Cattle; Cattle Diseases; Dietary Supplements; Female; Glucose; Growth Hormone; Insulin; Ins | 2023 |
The effect of dietary pioglitazone supplementation on milk yield, insulin sensitivity and GH-IGF-I axis in Holstein dairy cows during the transition period.
Topics: Animals; Cattle; Cattle Diseases; Dietary Supplements; Female; Glucose; Growth Hormone; Insulin; Ins | 2023 |
The effect of dietary pioglitazone supplementation on milk yield, insulin sensitivity and GH-IGF-I axis in Holstein dairy cows during the transition period.
Topics: Animals; Cattle; Cattle Diseases; Dietary Supplements; Female; Glucose; Growth Hormone; Insulin; Ins | 2023 |
The effect of dietary pioglitazone supplementation on milk yield, insulin sensitivity and GH-IGF-I axis in Holstein dairy cows during the transition period.
Topics: Animals; Cattle; Cattle Diseases; Dietary Supplements; Female; Glucose; Growth Hormone; Insulin; Ins | 2023 |
Combination of pioglitazone and clomiphene citrate versus clomiphene citrate alone for infertile women with the polycystic ovarian syndrome.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Ovulation Induction; Piog | 2021 |
Effects of dietary supplementation of pioglitazone or walnut meal on metabolic profiles and oxidative status in dairy cows with high pre-calving BCS.
Topics: Animal Feed; Animals; Body Composition; Cattle; Dietary Supplements; Feeding Behavior; Female; Hypog | 2018 |
Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome.
Topics: Adult; Female; Fertilization in Vitro; Follow-Up Studies; Humans; Ovary; Ovulation Induction; Piogli | 2010 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Topics: Adult; Area Under Curve; Blood Glucose; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resist | 2005 |
Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes.
Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Hispanic or Latino; Hu | 2006 |
Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes.
Topics: Adult; Carotid Artery Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Disease | 2008 |
Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome.
Topics: Adult; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infertility, Female; Pioglitaz | 2008 |
26 other studies available for pioglitazone and Pregnancy
| Article | Year |
|---|---|
PPARγ ligands modulate the immune response mediators in the pig myometrium - An in vitro study.
Topics: Animals; Antineoplastic Agents; Benzamides; Cytokines; Female; Gene Expression Regulation; Hypoglyce | 2021 |
Analysis of changes in the proteomic profile of porcine corpus luteum during different stages of the oestrous cycle: effects of PPAR gamma ligands.
Topics: Animals; Chromatography, Liquid; Corpus Luteum; Estrous Cycle; Female; Ligands; Pioglitazone; PPAR g | 2022 |
Dysregulated ACE/Ang II/Ang1-7 signaling provokes cardiovascular and inflammatory sequelae of endotoxemia in weaning preeclamptic rats.
Topics: Angiotensin II; Animals; Endotoxemia; Female; Humans; Losartan; Peptidyl-Dipeptidase A; Pioglitazone | 2022 |
Dysregulated glycolysis underpins high-fat-associated endometrial decidualization impairment during early pregnancy in mice.
Topics: Animals; Decidua; Endometrium; Female; Glycolysis; Mice; Mice, Inbred C57BL; Obesity; Pioglitazone; | 2023 |
The role of PPAR-γ in memory deficits induced by prenatal and lactation alcohol exposure in mice.
Topics: Animals; Child; Female; Fetal Alcohol Spectrum Disorders; Humans; Lactation; Memory Disorders; Mice; | 2023 |
Pioglitazone alleviates maternal sleep deprivation-induced cognitive deficits in male rat offspring by enhancing microglia-mediated neurogenesis.
Topics: Animals; Cognition; Cognitive Dysfunction; Female; Hippocampus; Male; Microglia; Neurogenesis; Piogl | 2020 |
Maternal high fructose-induced hippocampal neuroinflammation in the adult female offspring via PPARγ-NF-κB signaling.
Topics: Animals; Cytokines; Diet; Female; Fructose; Hippocampus; Inflammation; Inflammation Mediators; Male; | 2020 |
Dose-dependent effects of prenatal exposure of pioglitazone, the PPARγ agonist, on the hippocampus development and learning and memory performance of rat offspring.
Topics: Animals; Behavior, Animal; Dose-Response Relationship, Drug; Female; Gestational Age; Glial Fibrilla | 2021 |
Pioglitazone Ameliorates Lipopolysaccharide-Induced Behavioral Impairment, Brain Inflammation, White Matter Injury and Mitochondrial Dysfunction in Neonatal Rats.
Topics: Animals; Animals, Newborn; Behavior, Animal; Cytokines; Electron Transport Complex I; Encephalitis; | 2021 |
Catechol-O-Methyltransferase Deficiency Leads to Hypersensitivity of the Pressor Response Against Angiotensin II.
Topics: Angiotensin II; Animals; Catechol O-Methyltransferase; Drug Hypersensitivity; Female; Hypertension; | 2017 |
Role of Peroxisome Proliferator-Activated Receptor (PPARγ) in Metabolic Disorders in SGA with Catch-Up Growth.
Topics: Adult; Animals; Female; Humans; Infant, Newborn; Infant, Small for Gestational Age; Male; Metabolic | 2018 |
Peroxisome proliferator activated receptor gamma (PPAR-γ) ligand pioglitazone regulated gene networks in term human primary trophoblast cells.
Topics: Cells, Cultured; Female; Gene Expression Regulation; Gene Regulatory Networks; Humans; Hypoglycemic | 2018 |
Maternal immune activation-induced PPARγ-dependent dysfunction of microglia associated with neurogenic impairment and aberrant postnatal behaviors in offspring.
Topics: Animals; Behavior, Animal; Female; Hippocampus; Microglia; Neurogenesis; Pioglitazone; PPAR gamma; P | 2019 |
Pioglitazone reversed the fructose-programmed astrocytic glycolysis and oxidative phosphorylation of female rat offspring.
Topics: Animals; Astrocytes; Dietary Sugars; DNA, Mitochondrial; Female; Fetal Development; Fructose; Glucos | 2019 |
Pharmacological activation of peroxisome proliferator-activated receptor γ (PPAR-γ) protects against hypoxia-associated fetal growth restriction.
Topics: Altitude Sickness; AMP-Activated Protein Kinases; Animals; Disease Models, Animal; Female; Fetal Gro | 2019 |
Beneficial effects of pioglitazone, a selective peroxisome proliferator-activated receptor-γ agonist in prenatal valproic acid-induced behavioral and biochemical autistic like features in Wistar rats.
Topics: Animals; Anticonvulsants; Anxiety; Autism Spectrum Disorder; Brain Chemistry; Cytokines; Exploratory | 2019 |
Thiazolidinediones partially reverse the metabolic disturbances observed in Bscl2/seipin-deficient mice.
Topics: Adipocytes; Animals; Cells, Cultured; Energy Metabolism; Female; GTP-Binding Protein gamma Subunits; | 2013 |
Pioglitazone blocks ethanol induction of microglial activation and immune responses in the hippocampus, cerebellum, and cerebral cortex in a mouse model of fetal alcohol spectrum disorders.
Topics: Animals; Cerebellum; Cerebral Cortex; Disease Models, Animal; Ethanol; Female; Fetal Alcohol Spectru | 2015 |
Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Calcium; Calcium Channels; Calcium Signaling; Cells, | 2009 |
Protection of neurons and microglia against ethanol in a mouse model of fetal alcohol spectrum disorders by peroxisome proliferator-activated receptor-γ agonists.
Topics: Analysis of Variance; Animals; Brain; Cell Count; Cell Survival; Cells, Cultured; Disease Models, An | 2011 |
Improvement of insulin sensitivity promotes extravillous trophoblast cell migration stimulated by insulin-like growth factor-I.
Topics: Cell Movement; Cells, Cultured; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; In | 2013 |
Pioglitazone therapy in mouse offspring exposed to maternal obesity.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Female; Hypoglycemic Agents; Male; Metabolic Syndro | 2013 |
[Fatty liver. Not only ultrasound to be relied on!].
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Fatty Liver; Female; Hepatitis; Hepatitis C; Hep | 2003 |
Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-kappaB and JNK activation and suppression of COX-2 activity.
Topics: Animals; Cells, Cultured; Cyclooxygenase 2; Dopamine; Dose-Response Relationship, Drug; Drug Interac | 2007 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation.
Topics: 3T3 Cells; Adipose Tissue; Amino Acid Sequence; Angiopoietin-Like Protein 2; Angiopoietin-Like Prote | 2000 |